NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NOVAVAX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
NOVAVAX INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $685.04M | $213.20M | $547.89M | $1.55B | $0 | $0 | – | – | – | – | 61.0% | +221.3% |
| Nuvaxovid sales | $625.18M | $190.21M | $531.39M | – | – | – | – | – | – | – | 55.6% | +228.7% |
| Licensing, royalties, and other | $438.44M | $468.96M | $8.49M | $43.99M | – | – | – | – | – | – | 39.0% | -6.5% |
| Supply sales | $59.86M | $22.99M | $16.50M | – | – | – | – | – | – | – | 5.3% | +160.4% |
| Grants | $0 | $0 | $427.32M | $382.92M | $948.71M | $453.21M | $15.94M | $34.29M | $31.18M | $13.17M | 0.0% | – |
| Government Contract | – | – | – | – | – | $217.25M | $7.50M | $0 | $0 | $2.18M | – | – |
| Royalties and other | – | – | $24.99M | $43.99M | $197.58M | $22.39M | $2.73M | – | – | – | – | – |
| Sales-Based Royalties | – | – | $8.50M | $9.00M | $178.60M | – | – | – | – | – | – | – |
| Milestone Payments | – | – | $0 | $20.00M | $20.00M | – | – | – | – | – | – | – |
| License Fees and Sales Based Royalties | – | $398.20M | – | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest of North America | $575.67M | $4.46M | $13.39M | $194.48M | – | – | – | – | – | – | 51.2% | +12801.6% |
| United States | $405.61M | $522.54M | $443.89M | $382.92M | – | – | – | – | – | – | 36.1% | -22.4% |
| Rest of the world | $126.46M | $59.02M | $254.46M | $577.64M | – | – | – | – | – | – | 11.3% | +114.3% |
| Europe | $15.74M | $96.14M | $271.96M | $826.83M | – | – | – | – | – | – | 1.4% | -83.6% |
From the segment and revenue-disaggregation notes of Novavax's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.